We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byUriel Sherlock
Modified over 2 years ago
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis by Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Mauricio Pineda-Roman, Elias Anaissie, Joshua Epstein, John D. Shaughnessy, Maurizio Zangari, Guido Tricot, Abid Mohiuddin, Yazan Alsayed, Gail Woods, John Crowley, and Bart Barlogie Blood Volume 110(3):827-832 August 1, 2007 ©2007 by American Society of Hematology
Treatment schema. Frits van Rhee et al. Blood 2007;110:827-832 ©2007 by American Society of Hematology
Kaplan-Meier survival plots. Frits van Rhee et al. Blood 2007;110:827-832 ©2007 by American Society of Hematology
Kaplan-Meier plots of overall survival from landmarks of SFLC reduction. Frits van Rhee et al. Blood 2007;110:827-832 ©2007 by American Society of Hematology
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma Bart Barlogie, Guido J. Tricot, Frits van Rhee, Edguardo Angtuaco,
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma by Maurizio Chiriva-Internati, Zhiqing Wang, Emanuela Salati, Klaus.
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,
EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs) by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
The genetic basis of myelodysplasia and its clinical relevance
RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients by.
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.
Long-term outcome of patients in the LNH-98
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma by René-Olivier Casasnovas,
Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations by Susan Price, Pamela A. Shaw, Amy Seitz, Gyan Joshi, Joie.
Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis by Marcello Di Nisio, Anne W. S. Rutjes, Noemi.
Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.
Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,
Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo by Ilze Bot, Jian Guo, Miranda Van Eck,
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease by Monica L. Hulbert,
A systematic analysis of global anemia burden from 1990 to 2010 by Nicholas J. Kassebaum, Rashmi Jasrasaria, Mohsen Naghavi, Sarah K. Wulf, Nicole Johns,
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.
Effectiveness of Interferential Current Therapy in the Management of Musculoskeletal Pain: A Systematic Review and Meta-Analysis by Jorge P. Fuentes, Susan.
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson,
Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based.
A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
Optimal Use of Transplant for Myeloma Early-Late-nonablative Koen van Besien, MD, PhD Weill Cornell Medical College.
© 2017 SlidePlayer.com Inc. All rights reserved.